Last reviewed · How we verify
Abatacept Injection
At a glance
| Generic name | Abatacept Injection |
|---|---|
| Also known as | Rituximab, Orencia, ORENCIA |
| Sponsor | University of Erlangen-Nürnberg Medical School |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
- Study of COYA 302 for the Treatment of ALS (PHASE2)
- Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes (PHASE2)
- Abatacept for the Treatment of Giant Cell Arteritis (PHASE3)
- Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) (PHASE3)
- Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR) (PHASE2)
- Impact of T Cells on Age-related Vascular Dysfunction: A Translational Approach (EARLY_PHASE1)
- Novel Desensitization Kidney Transplantation (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abatacept Injection CI brief — competitive landscape report
- Abatacept Injection updates RSS · CI watch RSS
- University of Erlangen-Nürnberg Medical School portfolio CI